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It is projected that the elderly population 
in Indonesia will increase from approximately 
19 million people in 2010 with life expectancy 
of 69.8 years during period of 2005-2010 to 
29 million people in 2020 (11.11% of total 
population) with life expectancy of 73.6 years 
during period of 2020-2025. Higher elderly 
female proportion compared to male (11.43% 
versus 10.78%) will also be found.1 Aging 
process happens as people get older. Its process 
is influenced by genetic and environmental 
factors that can lead to successful aging, usual 
(normal) aging or pathologic aging. People with 
pathologic aging would have an increased risk 
to become frail.2,3
Nowadays, frailty syndrome is considered 
as one of the geriatric syndromes which 
increase the risk of worsening clinical outcome 
in mobility, functional status, hospitalization, 
institutionalization and mortality, as well as 
lower health-related quality of life.4,5 Moreover, 
frailty syndrome reflects a biological age that 
predicts mortality risk better than chronological 
age [RR 1.57 (95% CI 1.41-1.74) versus RR 
1.08 (95% CI 1.06-1.2)].6 No wonder, frailty 
syndrome has attracted clinician’s attention, 
especially the geriatricians, all over the world 
with increasing research in this field.
Frailty syndrome, a biological syndrome 
of decreased physiological reserved capacity 
and capability to endure upon stressors, can be 
perceived as a clinical syndrome (phenotype) 
or as deficits/co-morbidities/disabilities 
accumulation. Based on these two concepts, a 
person can be classified as normal (fit/robust), 
pre-frail, and frail.6,7
As  a  phenotype,  f ra i l ty  syndrome 
is characterized by exhaustion due to poor 
endurance and lack of energy, as well as decrease 
in body weight (shrinking), muscle strength 
(weakness), gait speed (slowness), and physical 
activity. This concept of phenotype frailty 
differentiates frailty from disability.6 In contrast, 
clinical approach of frailty syndrome as deficits 
accumulation takes into account disabilities in 
addition to co-morbidities as characteristics of 
frail people. This concept based on consideration 
that the more the deficits accumulated in a 
person, the frailer the person will be.7,8
There are numerous score systems to diagnose 
frailty syndrome, mostly derived from phenotype 
concept described by Fried et al.4 in cardiovascular 
health study or deficits accumulation concept 
described by Rockwood et al.7 in Canadian Study 
of Health and Aging. The prevalences of frailty 
syndrome differ one another depend on the score 
system or the clinical setting used in the study.8 The 
concept of frailty syndrome is multidimensional 
to include physical, psychological and social 
domain, in which complex interactions among 
them contribute to the development and the 
severity of frailty syndrome.9
Gill et al.10 shows the dynamic transition 
of frailty syndrome. It indicates that frailty 
syndrome is potentially reversible by managing 
modifiable contributing factors. Fried et al.4 
hypothesize the main element that contribute 
to physical frailty is sarcopenia (low of muscle 
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mass and function). Other conditions that 
may also contribute to development of frailty 
syndrome are inflammation, insulin resistance 
and diabetes mellitus (DM).11-13
Diabetes mellitus patients tend to have an 
accelerated aging process that increases the 
risk to become frail at younger age.14 Insulin 
resistance has long been known to contribute to the 
development of type 2 DM. Longitudinal studies 
have shown that insulin resistance [HR 1.15 (95% 
CI 1.02-1.31] and hyperglycemia/A1C ≥8% [HR 
3.33 (95% CI 1.24-8.93)] raise the incidence of 
frailty syndrome.12,13 Insulin resistance contributes 
to the increased inflammatory and pro-thrombotic 
state, endothelial dysfunction, atherosclerosis and 
changes in lipid metabolism. Insulin resistance 
has also been linked to sarcopenia with decreased 
gait speed and muscle strength.15 Therefore, in 
this Acta Medica Indonesiana-The Indonesian 
Journal of Internal Medicine edition, we bring 
this topic of frailty in relation to therapy in type 2 
DM elderly patients.
The oral anti-diabetic metformin is potentially 
able to modify factors contributing to frailty 
syndrome (insulin resistance, hyperglicemia, 
inflammation) through its activation on adenosine 
monophosphate-activated protein kinase (AMPK), 
while inhibiting mediator inflammation nuclear 
factor-ĸB (NFĸB) and mammalian target of 
rapamycin (mTOR).16,17 Moreover, animal studies 
show potential ability of metformin to delay aging 
process and prolong the animal’s life span with 
various length of time depend on the species and 
strain.18 Thus, the case-control study done by 
Sumantri et al.19 to explore the relation between 
metformin use in elderly diabetics and the risk of 
frailty syndrome is important in providing insight 
about another beneficial effect of metformin. This 
study indicates that metformin has a protective 
effect against frailty syndrome in elderly patients 
with type 2 DM. Surely this result will provide 
direction for future research in frailty syndrome 
intervention.
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